StreetInsider.com News Articles

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Wed, 17 Jun 2026 09:25:00 -0400

More People Than Ever Taking GLP-1 Drugs for Weight Loss

Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs

KELOWNA, BC / ACCESS Newswire / June 17, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides the following glucagon-like peptide-1 ("GLP-1") and obesity industry update.

On June 7^th, Novo Nordisk® ("Novo") announced that over three million Wegovy® pill prescriptions had been filled since its initial launch on January 5, 2026, in what they call "one of the strongest US pharmaceutical launches

GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand

Wed, 17 Jun 2026 09:25:00 -0400

More People Than Ever Taking GLP-1 Drugs for Weight Loss

Growing List of Diseases Now Indicated as Treatable With GLP-1 Drugs

Lexaria begins animal study on next-generation GLP-1 drugs

Tue, 09 Jun 2026 09:25:35 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that dosing has been completed in its animal study evaluating formulation enhancements with two next-generation glucagon-like peptide-1 drugs, retatrutide and amycretin, according to a company press release.

The study examines the compatibility of these drugs with Lexaria's DehydraTECH drug delivery technology. Retatrutide, owned by Eli Lilly and Company, is a triple hormone receptor agonist currently administered via weekly injections. The compound targets GLP-1, glucagon, and glucose-dependent insulinotropic polypeptide receptors.

Lexaria's study investigates oral dosing formulated via tablets and capsules for both retatrutide and amycretin, which is owned by Novo Nordisk. The research includes 18 different study

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Tue, 09 Jun 2026 09:25:00 -0400

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH^™

KELOWNA, BC / ACCESS Newswire / June 9, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that dosing has been completed in its 2026 Animal Study #2 (GLP-1-A26-2) evaluating a number of formulation enhancements with 2 next-generation glucagon-like peptide-1 ("GLP-1") drugs (the "Study") to explore the potential for improved DehydraTECH^TM performance as well as potentially stake new intellectual property claims.

Retatrutide is one of Eli Lilly and Company's^® leading next-generation

Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway

Tue, 09 Jun 2026 09:25:00 -0400

Retatrutide and amycretin are being investigated for compatibility with Lexaria's proprietary DehydraTECH^™

Retatrutide is one of Eli Lilly and Company's^® leading next-generation

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Wed, 03 Jun 2026 09:25:00 -0400

KELOWNA, BC / ACCESS Newswire / June 3, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, announces that it is attending the BIO International Convention ("BIO") from June 22-25 in San Diego, CA. Lexaria's attendance at last year's 2025 BIO convention served as a catalyst for its greatly expanded business development ("BD") program that is now starting to deliver positive results and which Lexaria intends to build upon at this year's BIO conference.

"We are experiencing record-high levels of business development

Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program

Wed, 03 Jun 2026 09:25:00 -0400

"We are experiencing record-high levels of business development

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

Tue, 19 May 2026 09:15:00 -0400

KELOWNA, BC / ACCESS Newswire / May 19, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, is pleased to announce that ethics approval has been received from an independent review board, for Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's^® commercially available Wegovy^® tablets (the "Study").

"Lexaria is delighted to have received the independent ethics review board approval so quickly," said Richard Christopher, CEO of Lexaria Bioscience. "Lexaria is looking for this Study to provide

Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7

Tue, 19 May 2026 09:15:00 -0400

"Lexaria is delighted to have received the independent ethics review board approval so quickly," said Richard Christopher, CEO of Lexaria Bioscience. "Lexaria is looking for this Study to provide

Lexaria Bioscience Releases Second Episode of Investor Video Series

Thu, 07 May 2026 09:25:00 -0400

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities

KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today released the second episode of Reformulated: Into the Mainstream, the Company's ongoing investor communications series.

The latest episode features CEO Rich Christopher in conversation with host Ana Berry. The discussion covers the recently announced extension of Lexaria's Material Transfer Agreement with a global pharmaceutical partner through year-end 2026, the Company's 2026 GLP-1

Lexaria Bioscience Releases Second Episode of Investor Video Series

Thu, 07 May 2026 09:25:00 -0400

CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities

Lexaria advances human study testing oral semaglutide formulations

Tue, 05 May 2026 09:11:40 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) submitted requests for ethics approval for Human Pilot Study #7, which will evaluate two oral DehydraTECH-semaglutide compositions against Novo Nordisk's Wegovy tablets.

The company completed final laboratory tablet composition work and commercial-scale manufacturing for the test articles. Third-party quality-control testing is currently underway. Lexaria anticipates completing ethics approval, quality-control testing and packaging by early June, with dosing expected to begin in mid-June.

The five-week parallel group study will investigate three separate arms to assess safety, tolerability and pharmacokinetic properties. The study will compare salcaprozate sodium-inclusive DHT-sema tablet and capsule formulations to commercially available Wegovy tablets under fasted

Lexaria advances human study testing oral semaglutide formulations

Tue, 05 May 2026 09:11:40 -0400

Lexaria Updates Progress on Human Study #7

Tue, 05 May 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema") compositions against Novo Nordisk's^® commercially available Wegovy^® tablets (the "Study").

Submissions have now been entered to formally request the required ethics approval from an independent review board. Final laboratory tablet composition work and commercial-scale manufacturing for the DHT-sema test articles for the Study have been completed with third-party independent lab quality-control

Lexaria Updates Progress on Human Study #7

Tue, 05 May 2026 09:10:00 -0400

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Fri, 01 May 2026 09:25:00 -0400

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy

KELOWNA, BC / ACCESS Newswire / May 1, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today announced the launch of Reformulated: Into the Mainstream, an ongoing investor communications series designed to support transparency, consistent engagement, and alignment with shareholders and the broader investment community.

As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews

Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications

Fri, 01 May 2026 09:25:00 -0400

Inaugural Episode Features CEO Rich Christopher on DehydraTECH Platform, GLP-1 Market Opportunity and Commercial Strategy

As Lexaria continues executing its strategy within the rapidly evolving GLP-1 and oral drug delivery landscape, the video series will feature regular interviews

Lexaria extends pharmaceutical partnership through december 2026

Wed, 29 Apr 2026 09:10:57 -0400

Lexaria Bioscience Corp. (NASDAQ: LEXX) announced the extension of its Material Transfer Agreement with an unnamed pharmaceutical company through December 31, 2026. The original agreement was signed on August 30, 2024.

The extension allows the pharmaceutical company additional time to receive and review Lexaria's 2026 research and development results related to GLP-1, according to the company's statement. The temporary exclusive license remains active during this period.

Lexaria has three ongoing GLP-1 studies currently in process: Human Study #7 and two animal studies. The company stated these studies are fully funded with existing corporate resources, with results expected during the third and fourth

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Wed, 29 Apr 2026 09:10:00 -0400

KELOWNA, BC / ACCESS Newswire / April 29, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on the Material Transfer Agreement ("MTA") originally entered into on August 30, 2024 with a pharmaceutical company ("PharmaCO") to evaluate Lexaria's DehydraTECH^™technology in a pre-clinical setting.

The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1. This allows the two

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Wed, 29 Apr 2026 09:10:00 -0400

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Thu, 23 Apr 2026 09:05:00 -0400

Contracts signed for Animal Study #2: GLP-1-A26-2
Amycretin and retatrutide to be tested for compatibility with DehydraTECH

KELOWNA, BC / ACCESS Newswire / April 23, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 Animal Study #2 (GLP-1-A26-2) that will evaluate a number of formulation enhancements with two next-generation glucagon-like peptide-1 ("GLP-1") drugs in animals (the "Study") to explore the potential for improved DehydraTECH performance

Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs

Thu, 23 Apr 2026 09:05:00 -0400

Contracts signed for Animal Study #2: GLP-1-A26-2
Amycretin and retatrutide to be tested for compatibility with DehydraTECH

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Tue, 21 Apr 2026 09:10:00 -0400

600,000 New Wegovy® Pill Prescriptions Written in First Two Months

KELOWNA, BC / ACCESS Newswire / April 21, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, provides this update of additional recent developments in the fast-moving glucagon-like peptide-1 ("GLP-1") oral (or "pill") market.

The GLP-1 oral pill sector is growing much faster in 2026 than expected, and faster than the pre-existing GLP-1 injectable sector. The industry's first-ever GLP-1 pill for weight loss, Wegovy^®, was approved by the US Food and Drug Administration ("FDA") on

Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales

Tue, 21 Apr 2026 09:10:00 -0400

600,000 New Wegovy® Pill Prescriptions Written in First Two Months

Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property

Wed, 15 Apr 2026 09:10:00 -0400

Contracts signed for Animal Study GLP-1-A26-1

KELOWNA, BC / ACCESS Newswire / April 15, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX), (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce the engagement of the contract research organization ("CRO") to execute and report on its 2026 animal Study #1 (GLP-1-A26-1) that will evaluate a number of formulation enhancements using both DehydraTECH-semaglutide ("DHT-sema") glucagon-like peptide-1 ("GLP-1") compositions and DehydraTECH-CBD ("DHT-CBD") compositions to explore the potential for additional improved performance as well as stake new intellectual property ("IP") claims (the "Study").

Contracts